Rare diseases
Investigational molecules
Locations
Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)
BulgariaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaSafety Study of NB-4746 with Riluzole and Placebo in Adults with Amyotrophic Lateral Sclerosis (ALS)
ItalyPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaEvaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus
FranceEfficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo
BelgiumLong-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
BelgiumBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
BelgiumOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
AustriaZenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
BulgariaLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
BelgiumBI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus
BulgariaTell us about your condition – we search every trial in Europe and connect you with the right site.
